A selection of recent successful placements and new projects globally. Focus in the 2nd quarter of 2021 has been predominantly Gene Therapy, Oncology, Synthetic Biology, Cardiovascular, CNS Diseases, Respiratory Diseases, Animal Health, Drug Delivery, Rare Diseases, Digital Therapeutics, P.O.C. Diagnostics and Implantable Technologies.
Author: Alison James
Coulter Partners was very pleased to partner recently with Memo Therapeutics AG, an innovator in the field of antibody discovery and development, to secure the appointment of Dr. George Badita as Chief Medical Officer. “George brings his extensive expertise in Translational Medicine and Clinical Drug Development as the company is in a pivotal stage of growth and prepares to transition to a clinical-stage organization. I thank the Coulter Partners team for their outstanding professional support in securing George’s appointment,” commented CEO, Dr. Karsten Fischer.
Coulter Partners was very pleased to partner recently with 2N Pharma, a biotech company developing therapeutic drugs to treat neurological disorders, to secure the appointments of Alex Leech as Chair of the Board of Directors and John Kemp as Non-Executive Director. Coulter Partners and BioInnovation Institute have a Partnership Agreement to support BII Creation House companies as they build and develop their Boards and Executive teams.
“The business proof is in the outcome and the metrics should convince any doubters that diversity always wins”
For the second in this series of interviews, Coulter Partners recently talked about the importance of diversity, equity and inclusion in Life Sciences with Dr. Jason Mellad, CEO and Co-Founder of Start Codon, a Cambridge based accelerator. Dr. Mellad was previously CEO of Cambridge Epigenetix, a company pioneering the development and application of novel epigenetics-based diagnostics and therapeutics.
“To be innovative, competitive and disruptive, we need to be inclusive.” In the first in a series of interviews with industry leaders about the importance of diversity, equity and inclusion in Life Sciences, Coulter Partners talks to Annalisa Jenkins, MBBS, FRCP. Dr. Jenkins serves as Chair and Independent Director on the boards of several Biopharma organisations and was previously President and CEO of Dimension Therapeutics.
Coulter Partners was delighted to partner again with Azitra Inc., to secure the appointment of Francisco Salva as President and Chief Executive Officer. Mr. Salva most recently served as President and Chief Executive Officer of Complexa, a clinical stage company developing innovative therapies for fibrotic and inflammatory diseases. Azitra is the first synthetic biology company focused on discovering and developing therapies to address serious skin conditions by harnessing the microbiome.
Each month, Coulter Partners hosts a virtual meeting, bringing together HR leaders from early-stage businesses to global pharmaceutical companies. The aim of the forum is to share practical ideas as a group of HR professionals, creating a rising tide to raise all boats. April’s forum focused on a New Frontier in Mental Health and Ultra-tailoring of Hybrid Organisations. Read on for the highlights…
A selection of recent successful placements and new projects globally. Focus in the 1st quarter of 2021 has been mainly on AI/Digital, Animal Health, Synthetic Biology, Vaccines, Diagnostics, CNS Diseases, Infectious Diseases, Immuno-oncology, Rare Diseases, Ophthalmology, Regenerative Medicine and Contract Manufacturing.
Coulter Partners was very pleased to partner recently with OxSonics® Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer, to secure the appointment of Dr Allison Jeynes as non-executive Chair of the Board of Directors.
At their first HR Leadership Forum of the year in January, Coulter Partners launched the HR & Talent Leadership Pulse. This survey is designed for senior HR and Talent leaders globally in Life Sciences, Healthcare and Digital Health. Please take part and help us build a comprehensive picture… Through 2020 we saw incredible transformations across organisations, with HR and Talent professionals leading the way. To support this community in 2021, Coulter Partners has created the pulse survey which will continue to run throughout the year and monitor developments.